%0 Journal Article
%T Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer: Retrospective Data Analysis from an Indian Centre
%A Amit Joshi
%A Kumar Prabhash
%A Vamshi Krishna Muddu
%A Vanita Noronha
%A Vijay Maruti Patil
%J Archive of "Case Reports in Oncology".
%D 2016
%R 10.1159/000447710
%X <bold>Objective:</bold> To determine the efficacy and safety of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) patients from the named patient programme (NPP) at our centre. <bold>Methods:</bold> mCRPC patients who progressed on docetaxel were given cabazitaxel intravenously every 3 weeks until disease progression or unacceptable toxicity occurred. Overall survival, progression-free survival, prostate-specific antigen response, quality of life (QOL) changes, and safety were reported. <bold>Results:</bold> Nine men received cabazitaxel (median: 7 cycles; range: 1¨C27) under the NPP and were followed until death. Median survival was 14.07 months (1.07¨C23.80) and progression-free survival was 2.67 months (1.07¨C20.27). QOL was stable for most patients. Common adverse events (grade ¡Ý3) were neutropenia (n = 8), anaemia (n = 4), and leucopenia (n = 4). <bold>Conclusion:</bold> These data from 9 patients are consistent with the results reported in the TROPIC study with a manageable safety profile
%K Cabazitaxel
%K Prostate-specific antigen
%K Disease-free survival
%K Neutropenia
%K Leucopenia
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5043265/